Brief: Satsuma Completes Enrollment In Pivotal Phase 3 Emerge Trial Of STS101 For Acute Treatment Of Migraine
01/06/2020 21:49
June 1 (Reuters) - Satsuma Pharmaceuticals Inc STSA.O :
* SATSUMA COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 EMERGE
TRIAL OF
STS101 FOR ACUTE TREATMENT OF MIGRAINE
* SATSUMA COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 EMERGE
TRIAL OF
STS101 FOR ACUTE TREATMENT OF MIGRAINE
Source text for Eikon: ID:nGNX2JDxnm
Further company coverage: STSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon